<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>244181</rcn>
  <id>190143893</id>
  <acronym>PAH-Advance</acronym>
  <teaser>ATXA Therapeutics has developed NTP42, a disruptive new drug for pulmonary arterial hypertension (PAH) and related cardiopulmonary (heart &amp; lung) diseases. NTP42 blocks the thromboxane receptor, a target at the root cause of PAH &amp; related diseases. By treating all clinical...</teaser>
  <objective>ATXA Therapeutics has developed NTP42, a disruptive new drug for pulmonary arterial hypertension (PAH) and related cardiopulmonary (heart &amp; lung) diseases. NTP42 blocks the thromboxane receptor, a target at the root cause of PAH &amp; related diseases. By treating all clinical hallmarks in both the LUNGS and HEART, NTP42 offers a game-changing solution for PAH leading to its rapid adoption once marketed. ATXAs Phase I clinical trial showed NTP42 is safe &amp; highly efficacious in man.

With EIC Blended Finance and VC co-investment, ATXA will undertake a Phase II trial on NTP42 in PAH. We will then secure a licensing deal with a pharma to ACCELERATE NTP42 to the PAH market (sales &gt;$1B at 5 yrs post-launch &amp; royalty returns to ATXA). With the proceeds of the licensing deal, we will DIVERSIFY uses of NTP42/pipeline drugs to treat other priority target diseases. This will also ENABLE growth (&gt;100 FTEs), transforming ATXA into a major European pharma with a diversified diseases &amp; drugs portfolio.</objective>
  <title>PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).</title>
  <totalCost>4181504.25</totalCost>
  <ecMaxContribution>2500000</ecMaxContribution>
  <startDate>2023-01-01</startDate>
  <endDate>2023-12-31</endDate>
  <ecSignatureDate>2022-12-19</ecSignatureDate>
  <duration>12</duration>
  <status>CLOSED</status>
  <identifiers>
    <grantDoi>10.3030/190143893</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2022-12-23 17:02:52</sourceUpdateDate>
  <contentCreationDate>2023-03-07 11:08:35</contentCreationDate>
  <contentUpdateDate>2023-05-24 17:28:21</contentUpdateDate>
  <lastUpdateDate>2025-09-19 14:49:09</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>440866</rcn>
        <id>440866-ntp42-a-novel-therapy-for-lung-and-heart-disease</id>
        <title>NTP42 – A novel therapy for lung and heart disease</title>
        <contentUpdateDate>2023-07-25 17:59:03</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55635</rcn>
        <title>HORIZON-EIC-2022-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2022-ACCELERATOR-01</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55635</rcn>
        <title>HORIZON-EIC-2022-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2022-ACCELERATOR-01</identifier>
      </call>
      <organization netEcContribution="2500000" totalCost="4181504.25" source="corda" order="1" ecContribution="2500000" terminated="false" sme="true" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1951806</rcn>
        <id>907542865</id>
        <vatNumber>IE3345642VH</vatNumber>
        <legalName>ATXA THERAPEUTICS LTD</legalName>
        <address>
          <street>TEMPLE CHAMBERS, 3 BURLINGTON ROAD</street>
          <city>Dublin</city>
          <postalCode>D04 RD68</postalCode>
          <country>IE</country>
          <geolocation>53.29417015,-6.1875107</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Dublin</name>
              <rcn>1465443</rcn>
              <nutsCode>IE061</nutsCode>
              <parents>
                <region>
                  <name>Eastern and Midland</name>
                  <rcn>1464994</rcn>
                  <nutsCode>IE06</nutsCode>
                  <parents>
                    <region>
                      <name>Ireland</name>
                      <rcn>305662504</rcn>
                      <nutsCode>IE0</nutsCode>
                      <parents>
                        <region>
                          <name>Ireland</name>
                          <rcn>305826344</rcn>
                          <nutsCode>IE</nutsCode>
                          <euCode>IE</euCode>
                          <isoCode>IE</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Ireland</name>
              <rcn>305826344</rcn>
              <nutsCode>IE</nutsCode>
              <euCode>IE</euCode>
              <isoCode>IE</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705792</rcn>
        <id>HORIZON.3.1</id>
        <code>HORIZON.3.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.1</pga>
        <title>The European Innovation Council (EIC)</title>
        <parent>
          <programme>
            <rcn>705791</rcn>
            <code>HORIZON.3</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>706909</rcn>
        <id>HORIZON_HORIZON-EIC-2022-ACCELERATOROPEN-01</id>
        <code>HORIZON-EIC-2022-ACCELERATOROPEN-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>EIC Accelerator Open</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456234</code>
              <title>Project financing</title>
              <displayCode>/Project financing</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43454386</code>
              <title>Market-creating innovation</title>
              <displayCode>/Market-creating innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450539</code>
              <title>Competitor analysis</title>
              <displayCode>/Competitor analysis</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450029</code>
              <title>Business model innovation</title>
              <displayCode>/Business model innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43451698</code>
              <title>Entrepreneurship</title>
              <displayCode>/Entrepreneurship</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453594</code>
              <title>Innovation support services</title>
              <displayCode>/Innovation support services</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43457773</code>
              <title>Spin-off companies</title>
              <displayCode>/Spin-off companies</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456213</code>
              <title>Product innovation</title>
              <displayCode>/Product innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43454395</code>
              <title>Marketing strategy</title>
              <displayCode>/Marketing strategy</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453822</code>
              <title>Investment readiness</title>
              <displayCode>/Investment readiness</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43452043</code>
              <title>Feasibility analysis</title>
              <displayCode>/Feasibility analysis</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43458031</code>
              <title>Sustainable innovation</title>
              <displayCode>/Sustainable innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450041</code>
              <title>Business support services</title>
              <displayCode>/Business support services</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43458163</code>
              <title>Technological innovation</title>
              <displayCode>/Technological innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43457365</code>
              <title>SME support</title>
              <displayCode>/SME support</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456414</code>
              <title>Public sector innovation</title>
              <displayCode>/Public sector innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456186</code>
              <title>Private investment</title>
              <displayCode>/Private investment</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453576</code>
              <title>Innovation management</title>
              <displayCode>/Innovation management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450521</code>
              <title>Company valuation</title>
              <displayCode>/Company valuation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43452100</code>
              <title>Financial &amp; Investment management</title>
              <displayCode>/Financial &amp; Investment management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43451181</code>
              <title>Due diligence</title>
              <displayCode>/Due diligence</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43451088</code>
              <title>Disruptive innovation</title>
              <displayCode>/Disruptive innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43458202</code>
              <title>Technology management</title>
              <displayCode>/Technology management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450026</code>
              <title>Business management</title>
              <displayCode>/Business management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450017</code>
              <title>Business development</title>
              <displayCode>/Business development</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43458661</code>
              <title>Venture capital</title>
              <displayCode>/Venture capital</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450014</code>
              <title>Business coaching and mentoring</title>
              <displayCode>/Business coaching and mentoring</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43456756</code>
              <title>Risk management</title>
              <displayCode>/Risk management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453837</code>
              <title>IPR management</title>
              <displayCode>/IPR management</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1189804</rcn>
        <id>190143893_14844_PUBLIHORIZON</id>
        <title>A Phase I Clinical Trial Assessing the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of NTP42:KVA4, a Novel Thromboxane Receptor Antagonist, in Healthy Subjects</title>
        <details>
          <authors>Kinsella BT, Reid HM, Mulvaney EP, Boyce M, Yamaoto T, Maginn M, Perkins C</authors>
          <journalNumber>207</journalNumber>
          <journalTitle>American Journal of Respiratory and Critical Care Medicine</journalTitle>
          <publishedPages></publishedPages>
          <publishedYear>2023</publishedYear>
          <publisher>American Thoracic Society</publisher>
        </details>
        <identifiers>
          <issn>1535-4970</issn>
          <doi>10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A3780</doi>
        </identifiers>
        <sourceUpdateDate>2024-01-25 07:46:10</sourceUpdateDate>
        <contentUpdateDate>2024-12-12 09:19:06</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/publication</code>
              <title>Project publication</title>
              <description>Result: Project publications</description>
              <displayCode>/Project publication</displayCode>
            </category>
            <category classification="projectPublication" type="isPublishedAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/CONFERENCE_PROCEEDING</code>
              <title>Conference proceedings</title>
              <displayCode>/Conference proceedings</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1036401</rcn>
        <id>190143893_12802_PUBLIHORIZON</id>
        <title>Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial</title>
        <details>
          <authors>Reid HM, Maginn M, Perkins CM, Mulvaney EP, Boyce M, Yamamoto T, Kinsella BT</authors>
          <journalNumber></journalNumber>
          <journalTitle>Frontiers in Pharacology</journalTitle>
          <publishedPages></publishedPages>
          <publishedYear>2023</publishedYear>
          <publisher>Frontiers Media S.A.</publisher>
        </details>
        <identifiers>
          <issn>1663-9812</issn>
          <doi>10.3389/fphar.2023.1296188</doi>
        </identifiers>
        <sourceUpdateDate>2024-01-25 07:46:10</sourceUpdateDate>
        <contentUpdateDate>2024-01-29 11:30:03</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/publication</code>
              <title>Project publication</title>
              <description>Result: Project publications</description>
              <displayCode>/Project publication</displayCode>
            </category>
            <category classification="projectPublication" type="isPublishedAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PEER_REVIEWED_ARTICLE</code>
              <title>Peer reviewed articles</title>
              <displayCode>/Peer reviewed articles</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1054261</rcn>
        <id>190143893_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - PAH-Advance (PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).)</title>
        <description>periodic</description>
        <teaser>Pulmonary arterial hypertension (PAH) is characterized by high blood pressure in the lungs due to obstruction of small lung arteries. The reduced blood flow makes it harder for the right side of the heart to pump blood to the lungs, leading to heart failure. While the current...</teaser>
        <sourceUpdateDate>2024-03-08 21:46:08</sourceUpdateDate>
        <contentUpdateDate>2024-03-13 09:52:14</contentUpdateDate>
        <relations>
          <associations>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/190143/190143893_PS/pah-advance-graphic-19jan24.jpg</uri>
              <alternativeText>Overview of ATXA's PAH-Advance Program</alternativeText>
              <mimetype>image/jpeg</mimetype>
              <size>148480</size>
            </webItem>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-EIC-ACC-BF</code>
        <title>HORIZON EIC Accelerator Blended Finance</title>
        <description>HORIZON EIC Accelerator Blended Finance</description>
        <displayCode>/HORIZON EIC Accelerator Blended Finance</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>